Can Patients With Recurrent or Primary Squamous Cell Carcinoma of the Anus in a Previously Irradiated Pelvis Receive Definitive Reirradiation?
Hyperfractionated accelerated reRT results in promising complete clinical response rates that appear to translate into durable pelvic control for patients with recurrent anal cancer or a new SCCA primary after prior pelvic radiation. Acute toxicity appears similar to initial standard chemoradiation, but limiting reRT doses to 39 Gy may reduce the risk of serious late toxicity.
Authors
- Van Karlyle Morris (ORCID: https://orcid.org/0000-0002-4911-2252)
- Emma B. Holliday (ORCID: https://orcid.org/0000-0002-4362-461X)
- Ethan B. Ludmir (ORCID: https://orcid.org/0000-0002-5472-5344)
- Eugene J. Koay (ORCID: https://orcid.org/0000-0001-7675-3461)
- Sonal S. Noticewala (ORCID: https://orcid.org/0000-0002-3153-0317)
- Jordan McDonald (ORCID: https://orcid.org/0000-0001-7982-0121)
- Ethan P. Damron (ORCID: https://orcid.org/0009-0002-1700-5978)
- Grace L. Smith (ORCID: https://orcid.org/0000-0002-3171-2911)
- Prajnan Das (ORCID: https://orcid.org/0000-0002-3845-0707)
- Bruce D. Minsky (ORCID: https://orcid.org/0000-0001-8434-7930)
- Craig A. Messick (ORCID: https://orcid.org/0000-0003-0714-5037)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Advances in Radiation Oncology
- Published
- 2025-11-09
- DOI
- https://doi.org/10.1016/j.adro.2025.101952
- Primary Topic
- Colorectal and Anal Carcinomas
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Genentech
- National Cancer Institute